Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines. An unusual study presented at the European Society of Cardiology (ESC) congress in ...
The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat has raised hope of an important new treatment option for people who struggle to control their blood pressure with current therapies.
Shell profit above, TotalEnergies in line with expectations amid lower prices Shell and TotalEnergies posted quarterly profit falls of 10% and 2%, respectively, on Thursday, dragged down by lower oil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback